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Introduction
Epithelial ovarian cancer (EOC) will be diagnosed in 24,400
women in the United States in 2004, with an estimated 14,300
deaths (Jemal et al., 2003). Neoplasms from the surface epithe-
lium of the ovary exhibit a variety of Müllerian-type cells, includ-
ing serous, mucinous, endometrioid, and clear cell, reflecting a
common pathway in embryological development. In the western
world, EOC is the most lethal gynecologic cancer, accounting
for more deaths than endometrial and cervical cancer com-
bined. Spread of the disease via the lymphatics and by peri-
toneal implantation is not associated with any specific signs or
symptoms, and the vast majority of women are diagnosed with
disseminated intraperitoneal carcinomatosis (FIGO Stage III).
Also contributing to the high mortality is the advanced age at
diagnosis (median 63 years), with an increase after
menopause. While ultrasound and computerized tomograms
are useful in definition of sites of bulk disease, surgical evalua-
tion is necessary for accurate staging and to remove large
metastases (cytoreduction). Due to the propensity for diffuse
small-volume disease, surgery is rarely able to render patients
disease free, and postoperative chemotherapy is usually
required. While overall mortality rates have remained relatively
constant for the past two to three decades, five-year survival
rates have increased from 30% in the 1960s to over 50% in the
past several years.
Etiology and cellular mechanism of epithelial ovarian
cancer
Consistent epidemiological data indicate that the risk of EOC
increases with the number of ovulatory events. For the last few
decades, two major theories, the incessant ovulation (Fathalla,
1971) and the gonadotropin hypotheses (Cramer and Welch,
1983), have been proposed to explain the same epidemiologi-
cal data (Riman et al., 1998). The incessant ovulation hypothe-
sis postulates that the repetitive wounding and recurring cell
proliferation in postovulatory repair of the ovarian surface
epithelium result in mutations accumulating in the epithelial
cells and ultimately tumor formation. This straightforward and
conceptually obvious explanation easily gained acceptance.
Support for this concept was also provided by laboratory exper-
iments demonstrating spontaneous transformation of rat ovari-
an surface epithelial cells following pronlonged subculturing
(Godwin et al., 1992; Testa et al., 1994). The passaging of the
cells in culture mimics repeated injury and proliferative repair of
ovarian surface epithelium imlied by incessant ovulation.
Recent experimental evidence supports the idea that higher
ovulatory activity is associated with more inclusion cysts and
other changes in the ovarian surface, such as invaginations. It
has been suggested that these inclusion cysts are a fertile envi-
ronment for ovarian cancer development (Feeley and Wells,
2001). In support of this hypothesis, many (but not all) studies of
the ovaries of ovarian cancer-prone individuals, i.e., women
with a family history of ovarian cancer and/or a deleterious
BRCA1 or BRCA2 mutation, have reported more changes in
their surface epithelium than control ovaries (Schlosshauer et
al., 2003).
The gonadotropin theory postulates that the surges of pitu-
itary gonadotropins that initiate each ovulation and persist in
high levels for years following menopause also stimulate the
ovarian surface epithelial cells and induce cell transformation.
Abundant epidemiological data and animal models exist to sup-
port this idea (Cramer and Welch, 1983). Gonadotropins have
unremarkable effects on ovarian surface epithelial cells in cul-
ture. Thus, inflammation of the ovarian epithelium was suggest-
ed as a mechanism by which gonadotropin stimulation and
ovulation contribute to ovarian cancer risk (Ness and Cottreau,
1999, 2000), since inflammation is a well-known factor con-
tributing to cancer (Ames et al., 1995). Ovulation is an inflam-
matory-like process involving multiple cytokines and proteolytic
enzymes, and their actions ultimately lead to tissue rupture
(Espey, 1994). Inflammation can also provide an explanation for
the increased risk associated with talc and asbestos exposure,
endometriosis and pelvic inflammatory disease, and mumps
viral infection. The ovarian epithelial inflammation caused by
ovulation or other factors may contribute to cancer risk by
increasing mutations in epithelial cells, as suggested (Ness and
Cottreau, 1999, 2000). However, gonadotropins may also stimu-
late an ovulation-like loss of the ovarian surface epithelial base-
ment membrane (Roland et al., 2003). The loss of basement
membrane may dramatically alter the biology of the epithelial
cells in tissue organization and cell contact signaling. For exam-
ple, the epithelial cells may upregulate their survival mecha-
nisms in the absence of an interacting extracellular basement
membrane, or the lack of basement membrane may favor the
selection of apoptosis-resistant cells. Thus, it can be postulated
that the frequent placement of the surface epithelium in such a
basement membrane-less state by repetitive gonadotropin
stimulation may lead to the selection of preneoplastic cells and
increase the chance for a subpopulation of the epithelial cells,
the cancer-prone cells with accumulated genetic mutations, to
transform (Zeimet and Marth 2003). Even after cessation 
of ovulation due to the depletion of follicles, the high levels of
gonadotropins immediately following menopause may still stim-
ulate the ovulation-like process involving the expression of
cytokines and proteolytic enzymes in the surface epithelial com-
partment (follicles are depleted) of the ovaries. The inflammato-
ry stimulation may lead to the loss of basement membrane of
the surface and inclusion cysts of ovarian epithelium, perhaps
contributing neoplastic transformation. Since the inflammation-
like ovulation is COX-2-dependent, this mechanism may also
provide support for the chemopreventive function of COX-2
inhibitors in ovarian cancer.
Although molecular mechanistic studies provide further
support for the incessant ovulation, gonadotropin stimulation,
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inflammation, and basement membrane loss hypotheses, all
the theories concerning the etiology of ovulation-associated
ovarian cancer are not mutually exclusive. Additional hypothe-
ses concerning steroid hormones and the retrograde transport
of carcinogens through fallopian tubes (Riman et al., 1998) may
also contribute to ovarian cancer risk in certain circumstances
and magnitude. The mechanism of gonadotropin-stimulated
basement membrane loss may not be mutagenic, but rather
promote the transformation of predisposed cells that have
acquired mutations from other events, such as ovulatory prolif-
eration and DNA modification by mutagens.
Genetics of ovarian cancer
Much remains to be discovered regarding the molecular events
that underlie ovarian cancer development. Both hereditary and
nonhereditary forms of EOC develop in a multistep process that
involves alterations in many specific genes. The normal ovarian
surface epithelial cell has multiple mechanisms that regulate its
growth and differentiation, and several separate events are
required to override these control mechanisms. The fundamen-
tal mechanisms underlying the genetic basis of cancer are con-
tinually being defined and redefined and involve alterations in a
number of genes, including protooncogenes, tumor suppressor
genes, and DNA repair genes. Ovarian cancers display defects
in many genes, including AKT, EGFR, ERBB2, RAS, PIK3CA,
MYC, DOC-2/DAB2, γ-synuclein (SNCG), and TP53, as well as
a myriad of cytogenetic abnormalities (Prowse et al., 2003).
These defects result from both genetic
and epigenetic changes and can occur
at varying frequencies in different patho-
logic subtypes, both early and late in the
transformation process. Genetic factors
that are unique to ovarian cancer have
been somewhat difficult to identify.Two of
the most well known genes associated
with susceptibility to breast and ovarian
cancer, BRCA1 and BRCA2, discovered
almost a decade ago, were expected to
illuminate not only the rare forms of
these inherited cancers, but the more
common forms (i.e., sporadic) as well.
Their roles in hereditary forms of ovarian
cancer are now well documented and
described below. However, initial enthu-
siasm for a significant role of these
genes in the pathogenesis of the approximately 95% of ovarian
cancers without a family history has waned somewhat. Somatic
mutations of BRCA1 and BRCA2 genes have proven rare, yet
epigenetic changes in the form of promoter methylation result-
ing in transcriptional silencing of the BRCA1 gene have been
demonstrated in about 5% to 10% of nonfamilial ovarian cancer
cases. In contrast, BRCA2 is generally hypomethylated and
overexpressed in ovarian cancers. The puzzle that endures is
why breast tissue, and ovarian tissue to a lesser extent, is so
susceptible to mutated BRCA1 and BRCA2. Hormonal factors,
such as estrogen, have been central to this hypothesis and are
under active investigation. A recent study has found that BRCA1
interacts specifically with, and is in part concentrated on, the
inactive X chromosome (Xi) in female somatic cells (Ganesan et
al., 2002). There, it interacts with the large, noncoding, Xi-
associated RNA, Xist, and promotes the proper localization of
Xist on Xi. In cells devoid of/depleted in BRCA1, Xi lacks 
both Xist and the specialized histone, MacroH2A (MH2A), and
shows signs of incomplete silencing. This may explain why
women, as opposed to men, so often develop cancer when they
have inherited a mutant gene. Dissecting BRCA1 and BRCA2
gene function has raised further excitement with regard to
uncovering additional cancer-associated genes. Recent studies
have found that BRCA2 and FANCD1, a gene associated with
Fanconi anemia, were one and the same (Howlett et al., 2002)
and that disruption of FA-BRCA pathway, which occurs in ovari-
an cancers, alters sensitivity to cisplatin (Taniguchi et al., 2003).
Novel BRCA1 and BRCA2 protein complexes are also being
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Figure 1. Ovarian tumors in Tg-MISIIR-TAgmice
A and B: H&E staining (A) and immunohisto-
chemical detection (B) of large T antigen (TAg)
protein of the ovarian carcinoma of a Tg-MISIIR-
TAg transgenic mouse. 
C and D: Magnetic resonance images (MRI) of
age-matched wild-type and Tg-MISIIR-TAg
transgenic mice. The normal ovary of the wild-
type mouse is indicated by the arrow in C and
the ovarian tumors are indicated by the arrows
in D. Images were acquired with a 2D spin-echo
pulse sequence, TR = 1200 msec, TE = 13 msec,
and 4 averages were acquired in a dedicated
animal MRI scanner at a field strength of 7 Tesla
for a total imaging time of 19 min. Prior to imag-
ing, the mice received an intramuscular injec-
tion of the contrast agent Gd-DTPA.
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discovered, and components of these complexes have been
shown to be abnormally expressed in cancer (Dong et al.,
2003). Like so many other BRCA discoveries regarding the
BRCA proteins, it is still not clear how these will all fit into the
bigger picture. However, proteins within this network are likely to
have implications in many cancers, including ovarian.
Experimental models of ovarian cancer
The lack of ovarian cancer-prone mammals has hampered our
ability to experimentally determine whether and how changes in
the surface epithelium occur and if they are an aspect of ovarian
oncogenesis. Recently, significant inroads have been made in
genetic modeling of EOC in immunocompetent mice (reviewed
by Nikitin et al., 2004). In one model, whole ovaries from mice
genetically engineered to express the avian retroviral receptor,
TVA, were isolated, cultured, and transduced with several onco-
gene-bearing avian retroviruses individually and in various
combinations. Reintroduction of ovarian cells exhibiting loss of
p53 in combination with a minimum of two oncogenic lesions,
including c-Myc, K-Ras, or Akt, to the ovarian bursa results in
the development of ovarian carcinoma in mice. Other investiga-
tors have shown that conditional inactivation of both the p53
and Rb tumor suppressor genes in the ovarian surface epitheli-
um of mice leads to the development of ovarian carcinomas in
97% of cases. Additionally, a transgenic mouse model of EOC
that recapitulates human disease by expression of the simian
virus 40 large and small TAg genes under control of the 5′
upstream regulatory sequences of the Müllerian inhibitory sub-
stance type II receptor (MISIIR) gene promoter has recently
been developed. Female TgMISIIR-TAg transgenic mice devel-
op bilateral ovarian adenocarcinomas (Figure 1) accompanied
by ascites and peritoneal implants. Although female TgMISIIR-
TAg transgenic mice are nearly always infertile, a stable trans-
genic line was derived from a male founder. Hopefully, these
models will lead to a better understanding of the biological basis
for ovarian cancer initiation, and aid in finding better ways to
prevent, treat, and diagnose this frequently fatal disease.
Screening and prevention
Epidemiologic studies have identified several factors that
increase a woman’s risk for EOC, including increasing age, a
family history of ovarian and/or breast cancer, and nulliparity.
Exposure to long-term (greater than 10 years) estrogen
replacement therapy confers a 2- to 3-fold increase in risk
(Lacey et al., 2002). The highest level of risk for ovarian cancer
is associated with germline mutations in BRCA1, BRCA2, and
the HNPCC genes (Narod and Boyd, 2002; Brown et al., 2001).
Estimates of the lifetime risk for ovarian cancer range from 16%
to 60% for BRCA1/2 mutation carriers. Among Ashkenazi
Jewish women, in whom one of the three founder BRCA muta-
tions has been found, lifetime ovarian cancer risks were 54% for
BRCA1 and 23% for BRCA2 mutations (King et al., 2003).
Clinical genetic testing and counseling are now available for
women suspected to have a hereditary susceptibility to ovarian
cancer to better define their risk profiles and to develop
appropriate preventive strategies. Recommendations fall into
four general categories: increased surveillance, surgical
prophylaxis, pharmacologic interventions (chemoprevention),
and lifestyle changes. Screening recommendations are prob-
lematic for ovarian cancer, for which no test or series of tests
have been found to be sufficiently sensitive and specific. The
identification of a precursor lesion to EOC would also facilitate
earlier diagnosis. Despite their limitations, however, many prac-
titioners have begun screening with the combination of pelvic
exam, transvaginal ultrasound, and CA-125, either annually or
semiannually, particularly in women with a strong family history
of ovarian cancer. In order to improve the positive predictive
value of screening strategies, current efforts are being directed
toward identifying novel molecular markers, including genomic
and proteomic markers (Petricoin et al., 2002), or panels of
markers which may be combined for use in conjunction with
ultrasonography to improve the predictive value of the screen-
ing process (Barnes et al., 2002). Prophylactic oophorectomy is
often considered by women with a family history of ovarian
cancer, particularly those who are BRCA1/2 mutation carriers,
due to the uncertain nature of screening and the high case-
fatality rate of advanced stage cancer. Recent studies have
demonstrated a greater than 90% reduction in ovarian cancer
and a 50% reduction in breast cancer among women under-
going oophorectomy for prophylaxis (Rebbeck et al., 2002).
Prophylactic surgery does not, however, eliminate the risk for
primary peritoneal cancer and may result in long-term adverse
physical and psychological sequelae. To date, there have been
no phase III randomized chemoprevention trials for ovarian can-
cer. However, because of the strong epidemiologic association
between oral contraceptive (OC) use and a reduction in ovarian
cancer rates, many gynecologists are recommending their use
in women with an increased risk, either due to family history or
nulliparity. While data from some studies of women with
BRCA1/2 mutations suggest that they enjoy the same degree of
protection (approximately 40%) from OCs as do women in the
general population, others have not found a protective effect,
and there is some concern about an increased risk for breast
cancer in this population. Small pilot studies are now underway
to determine the chemopreventive role of other agents, includ-
ing members of the retinoid family, progestational agents, and
COX-2 inhibitors. There is intense interest on the part of high-
risk individuals about opportunities to reduce their ovarian can-
cer risk by changes in diet, exercise, or other lifestyle
modifications. There is concern, for example, about exposure to
fertility drugs and their effect on ovulation. Unfortunately, most
of the factors linked to ovarian cancer risk are reproductive in
nature (e.g., nulliparity) and their manipulation is, therefore,
confounded by social concerns. The exact role of diet, micronu-
trient supplementation, and exercise remains elusive for ovarian
cancer, and any recommendations given must be on the basis
of general health and wellbeing.
Current treatment of epithelial ovarian cancer
EOC is considered to be a chemosensitive neoplasm, with ini-
tial overall response rates to systemic therapy exceeding 80%
when integrated with cytoreductive surgery. However, among
women with advanced-stage disease at diagnosis, long-term
survival remains poor due to eventual tumor recurrence and
emergence of drug-resistant disease.While effective cytoreduc-
tive surgery at the time of diagnosis has been correlated with
improved survival, the optimal integration of surgery and
chemotherapy remains to be determined. Primary postopera-
tive chemotherapy has evolved from single alkylating agents to
cisplatin and cisplatin-based combinations, followed by incorpo-
ration of paclitaxel and substitution of carboplatin for cisplatin,
but not without a degree of controversy. In particular, although
mature results from GOG111 (McGuire et al., 1996) established
the superiority of cisplatin-paclitaxel compared to cisplatin-
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cyclophosphamide, and GOG158 (Ozols et al., 2003) clearly
established that carboplatin-paclitaxel was at least as effective
as cisplatin-paclitaxel, other phase III trials, including GOG132
(Muggia et al., 2000) and ICON3 (ICON, 2002), have suggested
that sequential therapy with single-agent platinum followed by
paclitaxel can achieve equivalent outcomes. In spite of
improved median survival with carboplatin and paclitaxel, long-
term survival and disease mortality have remained largely
unchanged (Figure 2).
Recent phase III trials have evaluated a number of potential
strategies, including increased dose intensity of platinum or
paclitaxel, increased regional drug exposure through intraperi-
toneal delivery, and extended maintenance therapy. While each
of these approaches has been associated with increased toxici-
ty, none has yet achieved a meaningful improvement in quality-
adjusted survival or replaced the current standard of care.
In view of the central role of platinum, there has been partic-
ular interest in the incorporation of other active cytotoxic agents
that may accentuate the platinum response, including taxanes
(paclitaxel and docetaxel), gemcitabine, topotecan, polyethyl-
ene glycosylated (PEG)-liposomal doxorubicin, and prolonged
oral etoposide. In addition to their clinical activity in patients with
platinum-resistant disease, preclinical models have suggested
an advantage for platinum-based combinations with many of
these agents, which has been attributed to inhibition of path-
ways involved in the repair of platinum-DNA adducts. However,
it remains uncertain whether new platinum-based combinations
will actually achieve a better therapeutic index due to the
increased risk of toxicity. In addition, it is unclear whether opti-
mal combinations in EOC should utilize sequential single
agents, doublets, or triplets.
In developing the current phase III Gynecologic Cancer
Intergroup (GCIG) trial (GOG182-ICON5), it was elected to
include four experimental arms to evaluate the addition of three
new drugs (topotecan, gemcitabine, and PEG-liposomal doxoru-
bicin) using two different strategies for drug administration
(sequential doublets and triplet combinations) (Bookman, 2003).
Based on the current rate of accrual and events, it is anticipated
that an interim analysis will be performed in May 2004 and GOG
enrollment will be completed by October 2004, with extension of
enrollment at international sites. Results from GOG182-ICON5
will be maturing in conjunction with data from other international
randomized trials evaluating new combinations, including cis-
platin-topotecan, epirubicin, and gemcitabine.
Women with early stage disease (FIGO I and II) have a sig-
nificantly better prognosis than patients with advanced-stage
disease. Stage I patients with favorable prognostic factors have
more than a 90% cure rate with surgery alone. Early-stage
patients with unfavorable prognostic features (such as poorly
differentiated tumors or evidence of extracapsular spread
[FIGO Ic]) have a 70% to 80% cure rate. Recent clinical trials
have demonstrated that five-year survival can be improved from
74% to 82% with chemotherapy administered immediately after
diagnostic surgery compared to observation with chemotherapy
administered at relapse (Trimbos et al., 2003).
Targeted therapies for ovarian cancer
Future phase III trials will be driven by the rapid development of
novel compounds, including antiangiogenic reagents, human-
ized monoclonal antibodies, selective hormonal agents, and
small molecules that target key components in signal transduc-
tion pathways associated with cell growth, tumor vascularity,
and invasive potential. With rapid emergence of new agents, it
becomes important to efficiently and decisively evaluate as
many agents as possible. GOG182-ICON5 has demonstrated
that large multiarmed phase III trials appear feasible with inter-
national collaboration. However, it is also important to consider
other innovative strategies, such as dual (or bifactorial) design
and randomized phase II trials, coupled with a robust phase I–II
developmental therapeutics program to identify and evaluate
promising new agents and develop feasible combinations for
future phase III initiatives.
Thus far, most studies of targeted therapy in EOC have
focused on the epidermal growth factor receptor (EGFR), which
is expressed in 30% to 70% of EOC. Many of the cellular
processes associated with the malignant phenotype are initiat-
ed by activation of EGFR (Baselga, 2002). Receptor function
can be inhibited by blocking the binding of ligand by the recep-
tor, e.g., with monoclonal antibody (cetuximab, ABX-EGF) or
inhibition of the enzyme activity of the receptor tyrosine kinase
with small molecules, such as gefitinib or erlotinib.
These drugs have been evaluated in clinical trials. Erlotinib
was found to have a response rate of 8.8% as a single agent in
heavily pretreated patients (median: three prior regimens) with
ovarian cancer (Finkler et al., 2001). Gefitinib induced a
response and long-term stable disease in three additional
patients in 27 patients with similar characteristics (Schilder et
al., 2003). The two most common toxicities for these two agents
were mild to moderate acneiform rash and diarrhea. Similar tri-
als are planned with cetuximab and include correlative laborato-
ry studies, such as the levels of EGFR and phospho-EGFR
expression, measuring downstream effects, such as increase in
p27 in tumor biopsy specimens, and microarray analyses on
tumor tissue specimens before and after treatment with these
EGFR antagonists. It remains to be determined how these
agents will be best incorporated into combination chemothera-
F O C U S
Figure 2. Progression-free and overall survival for advanced ovarian cancer
Survival (upper curves) and progression-free survival (lower curves) for 790
stage III ovarian cancer patients following optimal cytoreduction (no
tumor nodule >1 cm) and treatment with either cisplatin plus paclitaxel or
carboplatin plus paclitaxel (GOG 158, Ozols et al., 2003). While median sur-
vival is almost five years, time to progression is less than two years. Median
survival after progression is two years.
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py earlier in treatment. However, erlotinib will undergo phase III
evaluation in combination with carboplatin and Taxotere
(SCOTROC) in advanced EOC. The next generation of EGFR
inhibitors will affect the interaction of erb-B family members. A
small molecular dual inhibitor, GW572016, blocks the activity of
the tyrosine kinase activity of EGFR and HER2. The antibody
pertuzumab (2C4) binds to the dimerization site of HER2,
inhibiting its interaction with other members of the erbB family
(Cho et al., 2003). Other agents that have shown promise in
preclinical systems await examination in the clinic as well (e.g.,
COX-2 inhibitors).
Vascular endothelial growth factor (VEGF) has a key role in
ascites formation associated with ovarian cancer. Antibody
against VEGF has been shown to prevent and even reverse
ascites formation in preclinical murine models bearing human
ovarian carcinoma xenografts (Hu et al., 2002). This activity did
not correlate with tumor response. Paclitaxel and anti-VEGF
antibody together resulted in decreased ascites and tumor
regression.These agents may work well together.VEGF induces
survivin, an inhibitor of apoptosis, and plays a role in mainte-
nance of microtubules, which is overexpressed in many common
cancers. It also promotes drug resistance through activation of
the PI3K/AKT pathway. The PI3K inhibitor, LY294002, enhances
the antitumor effects of paclitaxel on tumor growth and ascites
formation and decreases the development of drug resistance to
paclitaxel. Paclitaxel has complementary activity by inhibiting
VEGF expression in addition to its antimicrotubule mechanism of
action. Ascites fluid from cancer patients has been shown to
have higher levels of VEGF compared with ascites fluid from
patients with ascites due to benign causes (except frank infec-
tion) (Verheul et al., 2000). The ascites fluid of cancer patients
greatly increased the proliferation rate of human umbilical vein
endothelial cells in culture compared with ascites fluid from
patients with benign causes. This activity was inhibited by
SU5416, a tyrosine kinase inhibitor of the VEGF receptor, and
anti-VEGF. Thus, the results of ongoing clinical trials with beva-
cizumab are anticipated with great interest. Other molecules
also under clinical evaluation include imatinib in light of c-KIT
and PDGFR overexpression in a subset of ovarian cancers.
Replacing defective genes that cause the malignant behav-
ior of cancer cells is an interesting new approach to cancer ther-
apy. One such targeted gene is mutated TP53, which is the
most common defect associated with solid tumors and is
detected in greater than half of ovarian cancers. Mutations of
this gene are associated with shortened survival in patients with
ovarian cancer whose tumors carry this abnormality. Promising
preclinical data from in vitro systems and xenograft models led
to the conduct of phase I trials (Zeimet and Marth, 2003).These
studies showed that adenoviral vectors carrying wild-type p53
can be safely administered alone and in combination with plat-
inum-based chemotherapy with observed declines in CA-125.
Based on these data, a large, randomized trial was initiated in
previously untreated patients with optimally debulked disease.
Patients were assigned to receive either standard treatment
with six cycles of chemotherapy or the same chemotherapy
along with intraperitoneally administered adenovirus carrying
wild-type p53.The trial was closed after the first interim analysis
due to lack of any signs of efficacy. Reasons for this outcome
include faults in gene delivery, corrections of a single gene
defect in a solid tumor that may be inadequate, functional status
of gene after delivery, or interaction of the vector with host
defenses.
Several caveats already are evident with these new forms of
therapy. It is an oversimplification to attempt to categorize these
agents based purely on the anticipated molecular target. For
example, EGFR inhibitors have been demonstrated to also
potentiate antiangiogenic activity. In addition, in spite of encour-
aging preclinical models, early results from large, randomized
trials in other disease sites have not shown a benefit of adding a
molecularly targeted agent to a conventional chemotherapy
regimen as demonstrated by the recent INTACT trials in non-
small cell lung cancer (carboplatin and paclitaxel with or without
gefitinib). However, more recently, bevacizumab improved the
overall survival of patients with colon cancer when added to 5-
fluorouracil, leucovorin, and irinotecan.The presence of a target
on a tumor by itself may not be sufficient for these drugs to have
activity. It is likely that these compounds will only have activity in
the subset of patients where the target has a critical biological
role in the growth of the cancer, such as is seen with gain-of-
function mutations. New tools that will allow highly specific
tumor profiling, such as genomic microarray and proteomic
analyses, will facilitate more accurate patient selection for treat-
ment with these agents (Sawiris et al., 2002).
Future studies
While EOC has become more of a chronic disease, to signifi-
cantly impact on mortality will require advances in screening,
treatment, and prevention. Proteomic screening may lead to
earlier diagnosis, but large-scale validation of this technology is
still necessary. The current international randomized trial of dif-
ferent chemotherapy combinations will establish the regimen of
choice for the next decade, but it is unlikely that a major
improvement in survival will result from any combination of cur-
rent cytotoxic agents. To be effective, targeted therapy will
require molecular profiling to match biochemical abnormalities
in a patient’s tumor with a specific therapy. A better understand-
ing of the biology of ovarian cancer and the identification and
molecular characterization of a precursor lesion to invasive
EOC is essential to translational studies of prevention and early
diagnosis.
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